reference/19613425

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19613425

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, N.I.H., Extramural
endingPage	926
issn	1573-0646 0167-6997
issueIdentifier	5
pageRange	919-926
publicationName	Investigational New Drugs
startingPage	919
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6a3baa73eda4f07a95480b7268a5851c http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_e22f2e2582d6ccc310c069fdf49b9d5d
bibliographicCitation	Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Investigational New Drugs. 2018 Aug 07;36(5):919–26. doi: 10.1007/s10637-018-0630-9.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c341988e8599008a45820ebade28cd23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4a2ac9485fd5c2ba09a11f9383ad831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d78981379ecece16bdb15f5c0ba41b6b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8a058f88ce52d67ced98757d70380b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_727b6213e9d78840f0b39dc253d2acd5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_624c0db1d336b95da21657c2d0d99320 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e33209ab3cdbf0dd9b9c8aaad6338491 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e659bf9dc7bde75ccb87ff980e974d2f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca7bcc65ef11786e0d5a99270cfe18f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a95936aa71a6817fbf1e676537298ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1637bbb62088def70a317ece47fc645 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9921b65289d23ba1545702e094245328 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b4926608e04f3fb82d7f97282dab0a9c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a1aa02ec7c6fc5c2e5b5739fb086b46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_861688311cd860183c46dd90d78fc835 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0508-2987
date	2018-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/30083962 https://doi.org/10.1007/s10637-018-0630-9 https://pubmed.ncbi.nlm.nih.gov/PMC6153554
isPartOf	https://portal.issn.org/resource/ISSN/0167-6997 https://portal.issn.org/resource/ISSN/1573-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
discusses	http://id.nlm.nih.gov/mesh/M0018350 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0018278 http://id.nlm.nih.gov/mesh/M0549300 http://id.nlm.nih.gov/mesh/M0029482
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11494412 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d445950097f904f6fd5b28f1b37c3abf http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6957 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5957 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c4c4909eaa4fc41a39f0fa5c96f30cd6 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661

Total number of triples: 56.